Dorsal Raphe Nucleus Serotonergic Neurons Activity Is Necessary for the Manifestation of the Antidepressant Effect of Ketamine

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Mechanisms of the ketamine antidepressant effects observed in humans and laboratory animals are not fully understood. To further clarify the role of the brain serotonergic (5-HT) activity in the drug antidepressant action, optogenetic inhibition of 5-HT neurons in the rat dorsal raphe nucleus (DRN) was applied. In control animals, a subanesthetic dose of ketamine alleviated their depressive-like behavior in the tail suspension test. Inhibition of 5-HT neurons abolished the drug effect and moreover, a sedative response to ketamine was found under these conditions. Furthermore, optogenetic suppression of the activity of 5-HT neurons prevented the increase in c-Fos expression induced by ketamine both in light-sensitive neurons and in other DRN neurons. The data emphasize the key role of 5-HT neuron activity in the rapid ketamine antidepressant effect.

Sobre autores

U. Drozd

Institute of Cytology and Genetics SB RAS; Novosibirsk State University

Email: nchjournal@gmail.com
Russia, Novosibirsk; Russia, Novosibirsk

D. Lanshakov

Institute of Cytology and Genetics SB RAS; Novosibirsk State University

Email: nchjournal@gmail.com
Russia, Novosibirsk; Russia, Novosibirsk

N. Dygalo

Institute of Cytology and Genetics SB RAS; Novosibirsk State University

Email: nchjournal@gmail.com
Russia, Novosibirsk; Russia, Novosibirsk

Bibliografia

  1. Shishkina G.T., Dygalo N.N. // Zh. Vyssh. Nervn. Deyat. im. I.P. Pavlova. 2010. V. 60. № 2. P. 138–152.
  2. Liu B., Liu J., Wang M., Zhang Y., Li L. // Frontiers in Cellular Neuroscience. 2017. V. 11. P. 305.
  3. Pham T.H., Gardier A.M. // Pharmacology & Therapeutics. 2019. V. 199. P. 58–90.
  4. Krystal J.H., Abdallah C.G., Sanacora G., Charney D.S., Duman R.S. // Neuron. 2019. V. 101 № 5. P. 774–778.
  5. Yang C., Yang J., Luo A., Hashimoto K. // Translational Psychiatry. 2019. V. 9. № 1. P. 280.
  6. Zanos P., Moaddel R., Morris P.J., Riggs L.M., Highland J.N., Georgiou P., Pereira E.F.R., Albuquerque E.X., Thomas C.J., Zarate C.A., Jr. // Pharmacological Reviews. 2018. V. 70. № 3. P. 621–660.
  7. Miller O.H., Moran J.T., Hall B.J. // Neuropharmacology. 2016. V. 100. P. 17–26.
  8. Nosyreva E., Szabla K., Autry A.E., Ryazanov A.G., Monteggia L.M., Kavalali E.T. // Journal of Neuroscience. 2013. V. 33. № 16. P. 6990–7002.
  9. Gerhard D.M., Pothula S., Liu R.J., Wu M., Li X.Y., Girgenti M.J., Taylor S.R., Duman C.H., Delpire E., Picciotto M., Eric S., Wohleb E.S., Duman R.S. // The Journal of Clinical Investigation. 2020. V. 130. № 3. P. 1336–1349.
  10. Fukumoto K., Iijima M., Funakoshi T., Chaki S. // Neuropharmacology. 2018. V. 137. P. 96–103.
  11. Ago Y., Tanabe W., Higuchi M., Tsukada S., Tanaka T., Yamaguchi T., Igarashi H., Yokoyama R., Seiriki K., Kasai A., Nakazawa T., Nakagawa S., Hashimoto K., Hashimoto H. // International Journal of Neuropsychopharmacology. 2019. V. 22. № 10. P. 665–674.
  12. López-Gil X., Jiménez-Sánchez L., Campa L., Castro E., Frago C., Adell A. // ACS Chemical Neuroscience. 2019. V. 10. № 7. P. 3318–3326.
  13. Tiger M., Veldman E.R., Ekman C.J., Halldin C., Svenningsson P., Lundberg J. // Translational Psychiatry. 2020. V. 10. № 1. P. 159.
  14. Du Jardin K.G., Liebenberg N., Cajina M., Müller H.K., Elfving B., Sanchez C., Wegener G. // Frontiers in Pharmacology. 2018. V. 8. P. 978.
  15. Nishitani N., Nagayasu K., Asaoka N., Yamashiro M., Shirakawa H., Nakagawa T., Kaneko S. // International Journal of Neuropsychopharmacology. 2014. V. 17. № 8. P. 1321–1326.
  16. Warden M.R., Selimbeyoglu A., Mirzabekov J.J., Lo M., Thompson K.R., Kim S.Y., Adhikari A., Tye K.M., Frank L.M., Deisseroth K. // Nature. 2012. V. 492. P. 428–432.
  17. Challis C., Beck S.G., Berton O. // Frontiers in Behavioral Neuroscience. 2014. V. 8. P. 43.
  18. Kinoshita H., Nishitani N., Nagai Y., Andoh C., Asaoka N., Kawai H., Shibui N., Nagayasu K., Shirakawa H., Nakagawa T., Kaneko S. // International Journal of Neuropsychopharmacology. 2018. V. 21. № 3. P. 305–310.
  19. Fukumoto K., Iijima M., Chaki S. // Psychopharmacology. 2014. V. 231. № 11. P. 2291–2298.
  20. Du Jardin K.G., Liebenberg N., Müller H.K., Elfving B., Sanchez C., Wegener G. // Psychopharmacology. 2016. V. 233. P. 2813–2825.
  21. Gigliucci V., O’Dowd G., Casey S., Egan D., Gibney S., Harkin A. // Psychopharmacology. 2013. V. 228. № 1. P. 157–166.
  22. Fakhoury M. // Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2021.V. 106. P. 110094.
  23. Nishitani N., Nagayasu K., Asaoka N., Yamashiro M., Andoh C., Nagai Y., Kinoshita H., Kawai H., Shibui N., Liu B., Hewinson J., Shirakawa H., Nakagawa T., Hashimoto H., Kasparov S., Kaneko S. // Neuropsychopharmacology. 2019. V. 44. № 4. P. 721.
  24. McClure C., Cole K.L., Wulff P., Klugmann M., Murray A.J. // JoVE (Journal of Visualized Experiments). 2011. № 57. P. e3348.
  25. Шабурова Е.В., Ланшаков Д.А. // Биотехнология. 2020. Т. 36. № 5. С. 89–97.
  26. Paxinos G., Watson C. // The Rat Brain in Stereotaxic Coordinates. Academic Press, 1998.
  27. Lanshakov D.A., Sukhareva E.V., Kalinina T.S., Dygalo N.N. // Neurobiology of Disease. 2016. V. 91. P. 1–9.
  28. Bankhead P., Loughrey M.B., Fernández J.A., Dombrowski Y., McArt D.G., Dunne P.D., McQuaid S., Gray R.T., Murray L.J., Coleman H.G., James J.A., Salto-Tellez M., Hamilton P.W. // Scientific Reports. 2017. V. 7. № 1. P. 1–7.
  29. Krol A., Lopez-Huerta V.G., Corey T.E., Deisseroth K., Ting J.T., Feng G. // Frontiers in Neural Circuits. 2019. V. 13. P. 4.
  30. Pham T.H., Mendez-David I., Defaix C., Guiard B.P., Tritschler L., David D.J., Gardier A.M. // Neuropharmacology. 2017. V. 112. P. 198–209.
  31. Fukumoto K., Iijima M., Chaki S. // Neuropsychopharmacology. 2016. V. 41. № 4. P. 1046–1056.
  32. Dolzani S.D., Baratta M.V., Moss J.M., Leslie N.L., Tilden S.G., Sørensen A.T., Watkins L.R., Lin Y., Maier S.F. // Eneuro. 2018. V. 5. № 1.
  33. Hernández-Vázquez F., Garduño J., Hernández-López S. // Reviews in the Neurosciences. 2019. T. 30. № 3. C. 289–303.
  34. Drozd U.S., Lanshakov D.A. // Интегративная физиология. 2020. Т. 1. № 2. С. 144–146.
  35. Li Y.F. // Pharmacology & Therapeutics. 2020. V. 208. P. 107494.
  36. Seo C., Guru A., Jin M., Ito B., Sleezer B.J., Ho Y.Y., Wang E., Boada C., Krupa N.A., Kullakanda D.S., Shen C.X. // Science. 2019. V. 363. № 6426. P. 538–542.
  37. Zhou L., Liu D., Xie Z., Deng D., Shi G., Zhao J., Bai S., Yang L., Zhang R., Shi Y. // Frontiers in Behavioral Neuroscience. 2022. V. 16. P. 200.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar
2.

Baixar (83KB)
Metadados
3.

Baixar (105KB)
Metadados
4.

Baixar (2MB)
Metadados
5.

Baixar (485KB)
Metadados

Declaração de direitos autorais © У.С. Дрозд, Д.А. Ланшаков, Н.Н. Дыгало, 2023